Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1002-13.

Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.

Lorusso D, Ferrandina G, Fruscella E, Marini L, Adamo V, Scambia G.

Source

Department of Oncology, Catholic University of the Sacred Heart, Campobasso, Italy.

Abstract

Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown consistent activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogs, gemcitabine has been combined with carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of gemcitabine and other agents, including paclitaxel, is also feasible and has been actively studied in order to establish the role of gemcitabine in the management of treated and untreated ovarian cancer patients.

PMID:: 16343176; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Review Role of gemcitabine in ovarian cancer treatment. [Ann Oncol. 2006]
Review Role of gemcitabine in ovarian cancer treatment.
Lorusso D, Di Stefano A, Fanfani F, Scambia G. Ann Oncol. 2006 May; 17 Suppl 5:v188-94.
Review Gemcitabine in ovarian cancer. [Semin Oncol. 2001]
Review Gemcitabine in ovarian cancer.
Orlando M, Mandachain M. Semin Oncol. 2001 Jun; 28(3 Suppl 10):62-9.
Review Management of platinum-sensitive recurrent ovarian cancer. [Semin Oncol. 2006]
Review Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J, Ledermann JA. Semin Oncol. 2006 Apr; 33(2 Suppl 6):S12-6.
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. [J Clin Oncol. 2006]
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, et al. J Clin Oncol. 2006 Oct 10; 24(29):4699-707. Epub 2006 Sep 11.
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. [Int J Gynecol Cancer. 2005]
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
Pfisterer J, Vergote I, Du Bois A, Eisenhauer E, AGO-OVAR,, NCIC CTG, EORTC GCG. Int J Gynecol Cancer. 2005 May-Jun; 15 Suppl 1:36-41.

See reviews... See all...

Cited by 1 PubMed Central article

DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. [BMC Cancer. 2009]
DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells.
Unger FT, Klasen HA, Tchartchian G, de Wilde RL, Witte I. BMC Cancer. 2009 Oct 10; 9:359. Epub 2009 Oct 10.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Gemcitabine in epithelial ovarian cancer treatment: current role and future pers...
Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.
Int J Gynecol Cancer. 2005 Nov-Dec ;15(6):1002-13.

PubMed
Intra-person variability of various physical activity assessments in the Kuopio ...
Intra-person variability of various physical activity assessments in the Kuopio Ischaemic Heart Disease Risk Factor Study.
Int J Epidemiol. 1992 Jun ;21(3):467-72.

PubMed
A terminological and ontological analysis of the NCI Thesaurus.
A terminological and ontological analysis of the NCI Thesaurus.
Methods Inf Med. 2005 ;44(4):498-507.

PubMed
Detection of linkage under heterogeneity: comparison of the two-locus vs. admixt...
Detection of linkage under heterogeneity: comparison of the two-locus vs. admixture models.
Genet Epidemiol. 1992 ;9(1):61-6.

PubMed
The genesis and evolution of homeobox gene clusters.
The genesis and evolution of homeobox gene clusters.
Nat Rev Genet. 2005 Dec ;6(12):881-92.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Libraries

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information